Instructions for Use

IBL International GmbH
Flughafenstraße 52 a
22335 Hamburg, Germany

Tel. +49 (0) 40 53 28 91-0
Fax +49 (0) 40 53 28 91-11

IBL@tecan.com
www.tecan.com/ibl

Chromogranin A ELISA

Enzyme immunoassay for the quantitative determination of human Chromogranin in human serum and plasma (EDTA).

REF **RE53071**

Σ **96**

2°C 8°C

EU: IVD CE

IBL International GmbH
Flughafenstrasse 52a
22335 Hamburg, Germany

1. INTENDED USE

This ELISA (enzyme-linked immunosorbent assay) kit is intended for the quantitative determination of human chromogranin A levels in EDTA-plasma and serum samples. This test may be used as an aid for detecting patients with pheochromocytoma and neuroendocrine tumors (carcinoids). For in vitro diagnostic use only.

2. SUMMARY OF PHYSIOLOGY

Chromogranin A is a 49 kDa acidic protein that consists of 439 amino acids encoded on chromosome 14. Chromogranin A has been identified in a number of normal and neopastic endocrine tissues. It is demonstrated that an elevated level of circulating chromogranin A is a marker for tumors of neuroendocrine origin. However, the most significant clinical use of chromogranin A is related to the diagnostic procedure in patients with pheochromocytoma. The following is a short summary of the potential usages of chromogranin A.

1. A very sensitive (83%) and highly specific (96%) marker in the evaluation of actual or suspected pheochromocytoma. Drugs commonly employed in the diagnosis or treatment of pheochromocytoma have little effect on the plasma chromogranin A level, which is a great advantage of measuring chromogranin A over catecholamines.
2. To ascertain the source of a tumor. A high chromogranin A level indicates that the tumor arises from neuroendocrine tissues.
3. Endocrine tumors that do not produce their specific hormones, for example, calcitonin negative but chromogranin A positive C-cell carcinoma; zero-cell carcinoma; beta-cell carcinoma; parathyroid carcinoma.

3. ASSAY PRINCIPLE

This ELISA is designed, developed and produced for the quantitative measurement of human chromogranin A in EDTA-plasma or serum sample. The assay utilizes the two-site “sandwich” technique with two selected antibodies that bind to different epitopes of human chromogranin A.

Assay calibrators, controls and patient samples are added directly to wells of microplate that is coated with a polyclonal chromogranin A antibody. After the first incubation period, the antibody on the wall of microtiter well captures human chromogranin A in the sample and unbound protein in each microtiter well is washed away. Then a horseradish peroxidase (HRP)-labeled monoclonal anti-human chromogranin A antibody is added to each microtiter well and a “sandwich” of “monoclonal antibody – human chromogranin A – polyclonal antibody” is formed. The unbound monoclonal antibody is removed in the subsequent washing step. For the detection of this immunocomplex, the well is incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to the chromogranin A on the wall of the microtiter well is directly proportional to the amount of chromogranin A in the sample. A calibration curve is generated by plotting the absorbance versus the respective human chromogranin A concentration for each calibrator on point-to-point or cubical scales or 4 parameter curve fits. The concentration of human chromogranin A in test sample is determined directly from this calibration curve.

4. REAGENTS: Preparation and Storage

This test kit must be stored at 2 – 8°C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date.

MTP Microtiter Plate

Microplate coated with human chromogranin A antibody.	
Qty:	1 x 96 well microplate
Storage:	2 – 8°C
Preparation:	Ready to use

CAL A-F **LYO** **Standard A-F** lyophilized

Human chromogranin A in a lyophilized bovine serum albumin-based matrix with a ProClin preservative.	
Qty:	6 x Vials
Storage:	2 – 8°C (Lyophilized), <-20°C (Reconstituted) Do not exceed 3 freeze-thaw cycles.
Preparation:	Must be reconstituted with 0.5 mL of demineralized water, allowed to sit for 10 minutes, and mix microwell by inversions or gentle vortexing. Make sure that all solids are dissolved completely prior to use.

CONTROL 1-2 **LYO** **Control 1+2** lyophilized

Human chromogranin A in a lyophilized bovine serum albumin-based matrix with a ProClin preservative.	
Qty:	2 x Vials
Storage:	2 – 8°C (Lyophilized), <-20°C (Reconstituted) Do not exceed 3 freeze-thaw cycles.
Preparation:	Must be reconstituted with 0.5 mL of demineralized water, allowed to sit for 10 minutes, and mix microwell by inversions or gentle vortexing. Make sure that all solids are dissolved completely prior to use.

ENZCONJ Enzyme Conjugate

HRP-labeled anti-human chromogranin A monoclonal antibody in a stabilized protein matrix.	
Qty:	1 x 12 mL
Storage:	2 – 8°C
Preparation:	Ready to use

ASSAYBUF Assay Buffer

Phosphate-buffered saline with bovine serum albumin.	
Qty:	1 x 30 mL
Storage:	2 – 8°C
Preparation:	Ready to use

WASHBUF **CONC** **Wash Buffer** Concentrate (30x)

Surfactant in phosphate buffered saline with non-azide preservative.	
Qty:	1 x 30 mL
Storage:	2 – 25°C
Preparation:	Must be diluted with 870 mL distilled water and mixed well before use.

TMB SUBS TMB Substrate Solution

Tetramethylbenzidine (TMB) with stabilized hydrogen peroxide.	
Qty:	1 x 12 mL
Storage:	2 – 8°C
Preparation:	Ready to use

TMB STOP TMB Stop Solution

0.5 M sulfuric acid.	
Qty:	1 x 12 mL
Storage:	2 – 25°C
Preparation:	Ready to use

5. SAFETY PRECAUTIONS

The reagents must be used in a professional laboratory environment and are for in vitro diagnostic use. Source material which contains reagents of bovine serum albumin was derived in the contiguous 48 United States. It was obtained only from healthy donor animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these reagents as if they were potentially infectious. Avoid contact with reagents containing hydrogen peroxide. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes. Exercise Good Laboratory Practices.

6. MATERIALS REQUIRED BUT NOT PROVIDED

1. Precision single channel pipettes capable of delivering 25 µL, 50 µL, 100 µL, and 1000 µL
2. Repeating dispenser suitable for delivering 100 µL
3. Disposable pipette tips suitable for above volume dispensing
4. Disposable 12 x 75 mm or 13 x 100 glass or plastic tubes
5. Disposable plastic 100 mL and 1000 mL bottles with caps
6. Aluminum foil
7. Deionized or distilled water
8. Plastic microtiter well cover or polyethylene film
9. ELISA multichannel wash bottle or automatic (semi-automatic) washing system
10. Spectrophotometric microplate reader capable of reading absorbance at 450/650 nm or 450/620 nm
11. Calibrated timer

7. SPECIMEN COLLECTION & STORAGE

Only 30 µL total (15 µL each) of human EDTA-plasma or serum is required for human chromogranin A measurement in a duplicate. No special preparation of individual is necessary prior to specimen collection. Whole blood should be collected with lavender-top Vacutainer. Separate the plasma from cells by centrifugation at 850 – 1500 xg for 10 minutes. The plasma should be separated from the cells within one hour of blood collection and transferred to a clean test tube. **Plasma samples should be stored below –15ºC** if the assay is not to be performed within 72 hours. Otherwise, the plasma samples can be stored at room temperature for up to 72 hours. It is important that the plasma samples should not be stored at 2 – 8ºC for long-term storage. Avoid more than three freeze-thaw cycles of specimen.

Serum sample can also be used for chromogranin A measurement. Tests were performed with EDTA-plasma and serum sample from the same donor and it shows that serum gives almost the same chromogranin A level as EDTA-plasma by using this ELISA kit.

Collected EDTA-plasma samples should be shipped to designated laboratory in a frozen condition with dry ice. In case frozen condition is unavailable, samples should be shipped at room temperature in an insulated container for maximum 48 hour delivery. Samples should not be shipped with a blue ice pack or refrigerated.

8. ASSAY PROCEDURE

1. Reagent Preparation

(1) Prior to use allow all reagents to come to room temperature (20-25 ºC). Reagents from different kit lot numbers should not be combined or interchanged.

(2) Wash Buffer Concentrate must be diluted to working solution prior use. Please see REAGENTS section for details.

(3) Reconstitute all assay Standards and Controls by adding **0.5 mL** of demineralized water to each vial. Allow the standards and controls to sit undisturbed for 10 minutes, and then mix well by inversions or gentle vortexing. Make sure that all solids are dissolved completely prior to use. These reconstituted standards and controls must be stored at -20°C or below. Do not exceed 3 freeze-thaw cycles.

2. Assay Procedure

(1) Place a sufficient number of Antibody Coated microwell strips in a holder to run standards, controls and samples in duplicate.

(2) Test Configuration

Row	Strip 1	Strip 2	Strip 3
A	CAL A	CAL E	Sample 1
B	CAL A	CAL E	Sample 1
C	CAL B	CAL F	Sample 2
D	CAL B	CAL F	Sample 2
E	CAL C	CONTROL 1	Sample 3
F	CAL C	CONTROL 1	Sample 3
G	CAL D	CONTROL 2	Sample 4
H	CAL D	CONTROL 2	Sample 4

(3) Add **15 µL** of standards, controls and samples into the designated wells.

(4) Add **200 µL** of Assay Buffer to each well.

(5) Cover the plate with one plate sealer and aluminum foil. Incubate at **room temperature (20-25ºC)** and **shaking at 350 to 450 rpm** on an ELISA plate shaker for **90 minutes.**

(6) Remove the plate sealer. Aspirate the contents of each well. Wash each well **5 times** by dispensing **350 µL** of diluted Wash Buffer into each well, then completely aspirating the contents. Alternatively, an automated microplate washer can be used.

(7) Add **100 µL** of Enzyme Conjugate to each wells. Mix gently by tapping the plate.

(8) Cover the plate with one plate sealer and aluminum foil. Incubate at **room temperature (20-25ºC)** and **shaking at 350 to 450 rpm** on an ELISA plate shaker for **30 minutes**.

(9) Remove the plate sealer. Aspirate the contents of each well. Wash each well **5 times** by dispensing **350 µL** of diluted Wash Buffer into each well, then completely aspirating the contents. Alternatively, an automated microplate washer can be used.

(10) Add **100 µL** of TMB Substrate Solution into each of the wells. Mix by gently tapping the plate.

(11) Cover the plate with one plate sealer and aluminum foil. Incubate at **room temperature (20-25ºC)** for **20 minutes.**

(12) Remove the aluminum foil and plate sealer. Add **100 µL** of TMB Stop Solution into each of the wells. Mix by gently tapping the plate.

(13) Read the absorbance at **450/650 nm** or **450/620 nm** within **10 minutes** with a microplate reader.

9. PROCEDURAL NOTES

1. It is recommended that all standards, controls and unknown samples be assayed in duplicate. The average absorbance reading of each duplicate should be used for data reduction and the calculation of results.
2. Keep light-sensitive reagents in the original amber bottles.
3. Store any unused antibody-coated strips in the foil zipper bag with desiccant to protect from moisture.
4. Careful technique and use of properly calibrated pipetting devices are necessary to ensure reproducibility of the test.
5. Incubation times or temperatures other than those stated in this insert may affect the results.
6. Avoid air bubbles in the microwell as this could result in lower binding efficiency and higher CV% of duplicate reading.
7. All reagents should be mixed gently and thoroughly prior use. Avoid foaming.
8. We strongly recommend using 4-Parameter curve fit for control and patient sample calculation. Other curve fit programs such as Point-to-Point, Log-Log, Log-Linear, etc. may give a poor linear recovery.

10. INTERPRETATION OF RESULTS

The human chromogranin A concentrations for the controls and patient samples are read directly from the standard curve using their respective corrected absorbance.

Laboratory should report test results directly derived from the assay. For samples showing a higher than 90% value of the highest assay standard, it is strongly recommended that the patient sample is diluted 1:100 with assay buffer and re-assay the diluted sample for a more accurate test result. For example, the highest assay standard is about 550 ng/mL, any sample that shows a value greater than 500 ng/mL (90% of 550 ng/mL) should be repeated with 1:100 diluted sample. If the 1:100 diluted samples still shows a higher value than that of the highest assay standard, one can either report the sample value as greater than the highest assay standard (e.g. > 56 000 ng/mL) or further measure 1:10 000 diluted sample. It is preferred to obtain a diluted sample value located between standard B and D, wherein, this measured value is multiplied by the dilution factor to obtain the report value for the patient.

11. LIMITATIONS OF THE PROCEDURE

1. Since there is no Gold Standard concentration available for human chromogranin A measurement, the values of assay standards were established by correlation to a highly purified chromogranin A standard.
2. For sample values reading greater than the highest calibrator or 90% value of the highest calibrator, it is recommended to re-perform the assay with diluted samples.
3. Storing samples at refrigerated condition causes significant degradation of intact chromogranin A into small fragments. These fragments may cause interference of the assay resulting in false low test result.
4. Serum samples are not as stable as EDTA-plasma samples. Therefore, it is strongly recommended to use EDTA-plasma sample for chromogranin A measurement.
5. Bacterial or fungal contamination of plasma specimens or reagents, or cross-contamination between reagents may cause erroneous results.
6. Water deionized with polyester resins may inactive the horseradish peroxidase enzyme.

12. QUALITY CONTROL

To assure the validity of the results each assay should include adequate controls with known chromogranin A levels. We recommend that all assays include the laboratory’s own chromogranin A controls in addition to those provided with this kit.

13. EXPECTED VALUES

Seventy-two normal adult sera were measured with this Chromogranin A ELISA. The normal range was found to be less than 100 ng/mL. Five patients with pheochromocytoma showed a chromogranin A level of significantly over 100 ng/mL and one of them reached 400 000 ng/mL. It is highly recommended that each laboratory establish its own normal cut-off level. Paired EDTA-Plasma and Serum samples give almost the same values.
Although a chromogranin A level above 100 ng/mL would be an aid in clinical diagnosis, it is recommended to establish a baseline level of chromogranin A for each patient in order to monitor cancer patients after surgery, especially if this assay is used for the monitoring of prostate cancer patients. A clear surge of chromogranin A level would indicate an increased cancer cell activity.
Some endocrine diseases such as primary hyperparathyroidism, hyperthyroidism, or secondary hyperparathyroidism caused by chronic renal failure would also give a higher than normal chromogranin A level. It is reported that patients with rheumatoid arthritis, systemic lupus erythematosus would also cause higher chromogranin A level. Some therapeutic drugs that stimulate the endocrine system such as sexual hormone releasing hormone may also cause higher chromogranin A level in patient sample.

14. EXAMPLE DATA AND STANDARD CURVE

A typical absorbance data and the resulting standard curve from Chromogranin A ELISA are represented in a below table.

Well I.D.	Absorbance (readings at 450/620 nm)			Concentration (ng/mL)
	Readings	Average	Corrected	
CAL A: 0 ng/mL	0.035 0.032	0.033	0.000	
CAL B: 38 ng/mL	0.147 0.141	0.145	0.112	
CAL C: 99 ng/mL	0.287 0.289	0.288	0.255	
CAL D: 292 ng/mL	0.716 0.705	0.710	0.677	
CAL E: 716 ng/mL	1.351 1.386	1.368	1.335	
CAL F: 2500 ng/mL	2.686 2.700	2.693	2.660	
Control 1	0.222 0.239	0.230	0.197	74.4
Control 2	0.553 0.563	0.558	0.525	222.5



Note: This curve should not be used in lieu of calibrator curve run with each assay.

15. PERFORMANCE CHARACTERISTICS

Sensitivity

The LOD was determined by a sixteen replicates of two levels of calibrators (CAL A: 0 ng/mL and CAL B: 38 ng/mL) and was found to be 1.4 ng/mL.

Hook Effect

This assay has showed that it did not exhibit any high dose “hook” effect upto 1 000 000 ng/mL.

Reproducibility and Precision

The intra-assay precision was validated by measuring two control samples in a single assay with 12 replicate determinations and the inter-assay reproducibility was validated by measuring two control samples in duplicate of 16 individual assays. The results are summarized below:

Sample No.	Intra-assay Precision		Inter-assay Reproducibility	
	Mean (ng/mL)	CV (%)	Mean (ng/mL)	CV (%)
1	111.1 ng/mL	4.7%	69.1 ng/mL	5.9%
2	406.0 ng/mL	4.7%	216.9 ng/mL	3.7%

Linearity

Six samples were diluted with assay buffer and assayed. The results are summarized below:

Samples	Observed Concentration	Recovery (%)
Sample A	54.6 ng/mL	-
50%	23.7 ng/mL	84.0%
25%	11.8 ng/mL	83.4%
Sample B	138.4 ng/mL	-
50%	71.2 ng/mL	102.9%
25%	38.0 ng/mL	109.8%
Sample C	293.2 ng/mL	-
50%	155.2 ng/mL	105.9%
25%	74.7 ng/mL	101.9%
Sample D	610.8 ng/mL	-
50%	289.1 ng/mL	94.7%
25%	139.7 ng/mL	91.5%
Sample E	1543.4 ng/mL	-
50%	800.5 ng/mL	103.7%
25%	389.5 ng/mL	100.9%
Sample F	2500 ng/mL	-
50%	1124.3 ng/mL	90.0%
25%	593.0 ng/mL	94.9%

Interference

Interferent (Concentration tested, mg/mL)		Test (ng/mL)	Control (ng/mL)	Bias ($d_{obs,}$ %)
Bilirubin (EP07 recommended concentration: 0.05 mg/mL)	2.0	228.6	259.7	12.0%
	0.2	235.8	259.7	9.2%
	0.04	244.3	259.7	5.9%
Hemoglobin (EP07 recommended concentration: 2 mg/mL)	20.0	184.0	259.7	29.1%
	2.0	240.8	259.7	7.3%
	0.4	260.8	259.7	0.4%
Lipids (EP07 recommended concentration: 5 mg/mL)	400.0	55.6	58.4	4.8%
	40.0	59.0	58.4	1.0%
	20.0	56.2	58.4	3.8%
	6.0	258.9	256.7	0.3%

Spike Recovery

Three patient samples and three assay calibrators were combined at equal volumes and tested. The results are summarized below:

Samples	Observed Concentration (ng/mL)	Recovery (%)
Sample 1	90.1	-
Standard C: 99 ng/mL	102.6	108.5%
Standard D: 292 ng/mL	180.4	94.4%
Standard E: 716 ng/mL	357.1	88.6%
Sample 2	212.8	-
Standard C: 99 ng/mL	148.8	95.4%
Standard D: 292 ng/mL	220.0	87.2%
Standard E: 716 ng/mL	417.8	90.0%
Sample 3	341.0	-
Standard C: 99 ng/mL	233.9	106.3%
Standard D: 292 ng/mL	327.7	103.5%
Standard E: 716 ng/mL	510.3	96.6%

Assay Correlation Study

This assay was compared with Chromogranin A ELISA (RE53971). Both kits used the same antibody pair and were tested with 80 human plasma samples. The result is depicted in a below graph:



16. WARRANTY

This product is warranted to perform as described in its labeling and literature when used in accordance with all instructions. IBL International DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, and in no event shall IBL International be liable for consequential damages. Replacement of the product or refund of the purchase price is the exclusive remedy for the purchaser. This warranty gives you specific legal rights and you may have other rights, which vary from state to state.

17. REFERENCES

1. Pirker RA, Pont J, Pöhnl R, Schütz W, Griesmacher A, Müller MM. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med 1998;36:837-40.
2. Kimura N, Miura W, Noshiro T, Mizunashi K, Hanew K, Shimizu K, et al. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J 1997;44:319-27.
3. Hendy GN, Bevan S, Mattei MG, Mouland AJ. Chromogranin A. Clin Invest Med 1995;18:47-65.
4. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocrine Reviews: 1991;12:181-7
5. Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med 1989;320:444-7.

18. SHORT ASSAY PROCEDURE

(1) Add **15 µL** of the calibrators, controls, and samples into the designated microwells.

(2) Add **200 µL** of the assay buffer to each well.

(3) Mix, cover, and incubate at **room temperature (20-25 ºC)** and shaking at **350 - 450 rpm** for **90 minutes.**

(4) Wash each well five times.

(5) Add **100 µL** of the tracer antibody to each well.

(6) Cover and incubate at **room temperature (20-25 ºC)** with **shaking at 350 or 450 rpm** for **30 minutes.**

(7) Wash each well five times

(8) Add **100 µL** of substrate to each well.

(9) Cover and incubate at **room temperature (20-25 ºC)** for **20 minutes.**

(10) Add **100 µL** of the stop solution to each well.

(11) Read the absorbance at **450/650 nm** or **450/620 nm.**

Symbols / Symbole / Symboles / Símbolos / Simboli / Símbolos / Σύμβολα

REF	Cat.-No.: / Kat.-Nr.: / No.- Cat.: / Cat.-No.: / N.–Cat.: / N.º Cat.: / Αριθμός-Κατ.:
LOT	Lot-No.: / Chargen-Bez.: / No. Lot: / Lot-No.: / Lotto n.: / Lote N.º: / Αριθμός -Παραγωγή:
	Use by: / Verwendbar bis: / Utiliser à: / Usado por: / Da utilizzare entro:/ Usar até: / Χρησιμοποιείται από:
Σ	No. of Tests: / Kitgröße: / Nb. de Tests: / No. de Determ.: / Quantità dei tests: / N.º de Testes: / Αριθμός εξετάσεων:
CONC	Concentrate / Konzentrat / Concentré / Concentrar / Concentrato / Concentrado / Συμπύκνωμα
LYO	Lyophilized / Lyophilisat / Lyophilisé / Liofilizado / Liofilizzato / Liofilizado / Λυοφιλιασμένο
IVD	In Vitro Diagnostic Medical Device / In-vitro-Diagnostikum / Appareil Médical pour Diagnostics In Vitro / Dispositivo Médico para Diagnóstico In Vitro / Dispositivo Medico Diagnostico In vitro / Equipamento Médico de Diagnóstico In Vitro / Ιατρική συσκευή για In-Vitro Διάγνωση
BIO	Contains biological material of human origin / Enthält biologisches Material menschlichen Ursprungs / Contient une substance biologique d'origine humaine / Contiene material biológico de origen humano / Contiene materiale biologico di origine umana / Contém material biológico de origem humana / Περιέχει βιολογικό υλικό ανθρώπινης προέλευσης
BIO	Contains biological material of animal origin / Enthält biologisches Material tierischen Ursprungs / Contient une substance biologique d'origine animale / Contiene material biológico de origen animal / Contiene materiale biologico di origine animale / Contém material biológico de origem animal / Περιέχει βιολογικό υλικό ζωικής προέλευσης
UDI	Unique Device Identification / Eindeutige Gerätekennung / Identifiant de dispositif unique / Identificación única de producto / Identificatore univoco del dispositivo / Identificador de dispositivo único / Μοναδικός αναγνωριστικός κωδικός προϊόντος
	Read instructions before use / Arbeitsanleitung lesen / Lire la fiche technique avant emploi / Lea las instrucciones antes de usar / Leggere le istruzioni prima dell'uso / Ler as instruções antes de usar / Διαβάστε τις οδηγίες πριν την χρήση
	Keep away from heat or direct sun light / Vor Hitze und direkter Sonneneinstrahlung schützen / Garder à l'abri de la chaleur et de toute exposition lumineuse / Manténgase alejado del calor o la luz solar directa / Non esporre ai raggi solari / Manter longe do calor ou luz solar directa / Να φυλάσσεται μακριά από θερμότητα και άμεση επαφή με το φως του ηλίου
	Store at: / Lagern bei: / Stocker à: / Almacene a: / Armazenar a: / Conservare a: / Armazenar em: / Αποθήκευση στους:
2-8°C	Store at: 2 - 8°C / Lagern bei: 2 - 8°C / Stocker à: 2 - 8°C / Almacene a: 2 - 8°C / Armazenar a: 2 - 8°C / Conservare a: 2-8°C / Armazenar em: 2-8°C / Αποθήκευση στους: 2-8°C
	Manufacturer: / Hersteller: / Fabricant: / Productor: / Fabricante: / Fabbricante: / Παραγωγός:
	Distributor: / Distributor: / Distributeur: / Distributor: / Distributore: / Distribuidor: / Διανομέας:
	Caution! / Vorsicht! / Attention! / ¡Precaución! / Attenzione! / Cuidado! / Προσοχή!
	Symbols of the kit components see MATERIALS SUPPLIED. Die Symbole der Komponenten sind im Kapitel KOMPONENTEN DES KITS beschrieben. Voir MATERIEL FOURNI pour les symbôles des composants du kit. Símbolos de los componentes del juego de reactivos, vea MATERIALES SUMINISTRADOS. Per i simboli dei componenti del kit si veda COMPONENTI DEL KIT. Para símbolos dos componentes do kit ver MATERIAIS FORNECIDOS. Για τα σύμβολα των συστατικών του κιτ συμβουλευτείτε το ΠΑΡΕΧΟΜΕΝΑ ΥΛΙΚΑ.

Generic table, not all symbols are present in the product

COMPLAINTS: Complaints may be submitted initially written or vocal. Subsequently they need to be filed including the test performance and results in writing in case of analytical reasons.

WARRANTY: The product is warranted to be free from material defects within the specific shelf life and to comply with product specifications delivered with the product. The product must be used according to the Intended use, all instructions given in the instructions for use and within the product specific shelf life. Any modification of the test procedure or exchange or mixing of components of different lots could negatively affect the results. These cases invalidate any claim for replacement.

LIMITATION OF LIABILITY: IN ALL CIRCUMSTANCES THE EXTENT OF MANUFACTURER'S LIABILITY IS LIMITED TO THE PURCHASE PRICE OF THE KIT(S) IN QUESTION. IN NO EVENT SHALL MANUFACTURER BE LIABLE FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING DAMAGES FOR LOST PROFITS, LOST SALES, INJURY TO PERSON OR PROPERTY OR ANY OTHER INCIDENTAL OR CONSEQUENTIAL LOSS.

The labelling of hazardous substances is according to European directive.
For further country-specific classifications, please refer to the corresponding safety data sheet.

IBL International GmbH
Flughafenstrasse 52a
22335 Hamburg, Germany
Phone: +49 (0)40-53 28 91-0
Fax: +49 (0)40-53 28 91-11
IBL@tecan.com
www.tecan.com/ibl

Always there for you